Literature DB >> 31399374

Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?

Vikram Premkumar1, Raymond Comenzo2, Suzanne Lentzsch3.   

Abstract

Entities:  

Keywords:  BCL2; BELLINI; Targeted therapy; t(11;14)

Mesh：

Substances：

Year:  2019        PMID： 31399374      PMCID： PMC6954683          DOI： 10.1016/j.clml.2019.07.003

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  4 in total

1.  Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.

Authors:  Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Mark R Litzow; Kimberly J Henderson; Scott A Van Wier; Greg J Ahmann; Rafael Fonseca
Journal:  Blood       Date:  2005-06-23       Impact factor: 22.113

2.  Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.

Authors:  Philippe Moreau; Asher Chanan-Khan; Andrew W Roberts; Amit B Agarwal; Thierry Facon; Shaji Kumar; Cyrille Touzeau; Elizabeth A Punnoose; Jaclyn Cordero; Wijith Munasinghe; Jia Jia; Ahmed Hamed Salem; Kevin J Freise; Joel D Leverson; Sari Heitner Enschede; Jeremy A Ross; Paulo C Maciag; Maria Verdugo; Simon J Harrison
Journal:  Blood       Date:  2017-08-28       Impact factor: 22.113

Review 3.  Use of novel therapies in the treatment of light chain amyloidosis.

Authors:  Cindy Varga; Stephanie E Titus; Denis Toskic; Raymond L Comenzo
Journal:  Blood Rev       Date:  2019-05-22       Impact factor: 8.250

4.  Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

Authors:  Shaji Kumar; Jonathan L Kaufman; Cristina Gasparetto; Joseph Mikhael; Ravi Vij; Brigitte Pegourie; Lofti Benboubker; Thierry Facon; Martine Amiot; Philippe Moreau; Elizabeth A Punnoose; Stefanie Alzate; Martin Dunbar; Tu Xu; Suresh K Agarwal; Sari Heitner Enschede; Joel D Leverson; Jeremy A Ross; Paulo C Maciag; Maria Verdugo; Cyrille Touzeau
Journal:  Blood       Date:  2017-10-10       Impact factor: 22.113
  4 in total
  4 in total

Review 1.  Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives.

Authors:  Shayna Sarosiek; Vaishali Sanchorawala
Journal:  J Blood Med       Date:  2019-10-23

2.  Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.

Authors:  Vikram J Premkumar; Suzanne Lentzsch; Samuel Pan; Divaya Bhutani; Joshua Richter; Sundar Jagannath; Michaela Liedtke; Arnaud Jaccard; Ashutosh D Wechalekar; Raymond Comenzo; Vaishali Sanchorawala; Bruno Royer; Michael Rosenzweig; Jason Valent; Stefan Schönland; Rafael Fonseca; Sandy Wong; Prashant Kapoor
Journal:  Blood Cancer J       Date:  2021-01-11       Impact factor: 11.037

3.  Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers.

Authors:  Virág Réka Szita; Gábor Mikala; András Kozma; János Fábián; Apor Hardi; Hussain Alizadeh; Péter Rajnics; László Rejtő; Tamás Szendrei; László Váróczy; Zsolt Nagy; Árpád Illés; István Vályi-Nagy; Tamás Masszi; Gergely Varga
Journal:  Pathol Oncol Res       Date:  2022-02-28       Impact factor: 3.201

Review 4.  Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications.

Authors:  Linchun Xu; Yongzhong Su
Journal:  Exp Hematol Oncol       Date:  2021-07-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.